Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Locally advanced basal cell carcinoma (BCC) presents a treatment challenge for patients unsuitable for surgery or radiation.
• The Hedgehog signaling pathway plays a critical role in BCC development and progression.

Purpose of the Study:

• To review the efficacy, safety, and tolerability of sonidegib for locally advanced BCC.
• To discuss the clinical management of locally advanced BCC using sonidegib.

Main Methods:

• Review of findings from the phase 2 BOLT trial.
• Analysis of objective response rates, duration of response, and progression-free survival.
• Evaluation of adverse events and patient tolerability.

Main Results:

• Sonidegib (200 mg) achieved a 61% objective response rate in locally advanced BCC patients.
• Mean time to response was 4 months, with a median duration of response of 26.1 months.
• Most common adverse events included muscle spasms, hair loss, and taste disturbance, primarily grade 1 or 2.

Conclusions:

• Sonidegib is an effective treatment option for locally advanced BCC.
• The drug exhibits a manageable safety profile with common, generally mild adverse events.
• Sonidegib offers a valuable therapeutic strategy for patients with BCC unresponsive to conventional treatments.